Background: This study explores the association of insulin-induced weight (wt) gain on car-
Cardiovascular Risk in Diabetes (ACCORD) study, which was designed to investigate whether an aggressive therapeutic strategy to achieve tight glucose target (HbA 1c < 6.5%) would reduce CV events, surprisingly showed increased mortality in the intensively treated group. 8 The mean body mass index (BMI) of patients in the study was 32.2 kg/m 2 , and weight gain by more than 10 kg occurred in 27.8% of the intensively treated patients compared with 14.1% in the standard therapy. While a causal relationship between weight gain and adverse CV outcomes cannot be assumed, retrospective studies have shown that people with diabetes who actively lose weight improve not only their risk profile [9] [10] [11] but also survival rate. The aim of the present study, therefore, was to explore the association of insulininduced weight (wt) gain on CV outcomes and mortality in patients with T2D following insulin initiation by using evidence from realworld data. Several studies have validated and shown it to be demographically representative of the UK population in demography, disease prevalence, and mortality. 12, 13 We have also used it previously to evaluate diabetes-related outcomes in routine clinical practice. [14] [15] [16] Ethical approval was obtained from the South-East Research Ethics Committee.
| Study population
All adult T2D insulin users, aged 18 and above, were eligible for inclusion. Furthermore, these patients must have initiated insulin therapy between January 2007 and 2014 irrespective of previous or concurrent use of other glucose-lowering therapies. Patients with history of CV diseases prior to insulin initiation were excluded from the study.
Additionally, to minimise the prevalent user bias, patients with diagnoses of CV diseases (nonfatal MI and stroke) on insulin initiation or up to 180 days after were also excluded, while patients with type 1 diabetes
were not eligible for inclusion in the study. Figure 1 is a flow chart illustrating how the study cohort was derived.
| Exposure and outcome
We defined the exposure as change in weight, 1 year postinsulin initiation. Change in weight was measured by the difference between the baseline weight (at insulin initiation) and the weight after 1 year, measured in kilogram. There was no consideration on the specific type or mode of administration of insulin. We classified the change in weight after 1 year of initiating insulin into 5 categories based on the average weight change of 5 kg within this period as reported by previous studies. 2 Change in weight was classified into the following categories: >5 kg wt loss, 1.0 to 5.0 kg wt loss, no wt change, 1.0 to 5.0 kg wt gain, and >5.0 kg wt gain. Participants were followed up for 5 years to the earliest of the occurrence of any of the defined composite outcome, loss to follow-up (transfer out of practice), and discontinuation of insulin therapy, or at the end of the study after 5 years.
The study outcome was time to a 3-point composite of all-cause mortality, nonfatal myocardial infarction (MI) and nonfatal stroke.
Appropriate READ CODES were used to identify and extract these outcomes from the THIN database.
| Covariates
Baseline variables were selected a priori based on clinical significance.
These were extracted within the time period extending 90 days before and after initiation of insulin. These covariates included base- 
| Statistical analyses
Baseline variables were summarised within these categories of weight change by using mean values and standard deviation (SD) for continuous variables and frequencies (%) for categorical variables.
The differences between these baseline categories were analysed by using Pearson χ 2 tests or linear regression and summarised in a table.
Missing data among the exposure variable (weight) and other baseline covariates in the dataset were generally accounted for using multiple imputations with the chained equation model.
The primary analysis was time to a 3-point composite outcome of nonfatal MI, nonfatal stroke, and all-cause mortality. Crude and adjusted Kaplan-Meier estimates of survival functions were obtained for the categories of weight change with log-rank test comparing the equality of the survival curves between them. From these survival functions, the absolute reduction in the probability of an event occurring within a 5 year follow-up was determined.
We fitted a Cox proportional regression model to estimate the marginal hazard ratios and quantify the adjusted hazard of an event occurring in all the quintile groups compared with the third (no weight change) group. Covariates that had significant association in our univariate analysis at a P value ≤0.05 were included and adjusted for in the final model. Violations of the proportional hazard assumptions were confirmed through Schoenfeld residuals test.
| Subgroup/sensitivity analyses
Additional sensitivity analyses were carried out to evaluate the robustness of our data. We examined the assumption of no unmeasured covariate by examining if any unmeasured covariate would influence the measure of effect. Also, we compared the results of the study outcome between the datasets with missing data and the imputed data. This is to assess the reliability of these outcomes and any possible impact any missing data might have on them. Additionally, the exposure was reclassified as quintiles of weight change, and the outcomes were compared with our results. Subgroup analyses were performed on patients with BMI > 30 kg/m 2 to estimate the impact of weight changes on adverse composite outcomes in the obese population.
Point estimates with 95% confidence intervals (CIs) at the conventional statistical significance level of 0.05 were used in the regression models. All analyses were conducted by using Stata software, version 14. 17 The study was reported by using the Strengthening the Reporting of Observational Studies in Epidemiology criteria for reporting observational studies.
3 | RESULTS
| Cases and total follow-up
A total of 18,814 adult T2D patients, identified in the UK primary care electronic records via THIN database, fulfilled our inclusion criteria. In 
| Patients' characteristics
The overall mean age was 61.5 (SD: 13.6) years with a mean HbA 1c of 8.7% (SD: 1.8) and higher proportion (53.2%) of men. The 1.0 to 5.0 kg group was younger, while the weight neutral group had lower HbA 1c .
The overall mean weight was 91.3 kg, but the group who lost more than 5 kg had a greater weight of 96.6 kg. Summarily, significant differences were observed between the categories in socioeconomic status (P = .05), alcohol intake (P = .048), and use of lipid-lowering agents FIGURE 1 Flow diagram illustrating the selection of the study cohort (P = .0001). Table 1 summarises the baseline characteristics of the study cohort by the categories of change in weight 1 year after the initiation of insulin. The proportions of recorded data observed to be missing for weight were 15.8% and 36.5% at baseline and after 1 year were respectively. These were noted to be missing at random.
| Crude event rates
Although the probability of survival was similar (99%) between the weight categories at 1 year, there was a general decrease at 5 years in all the weight-change categories. This ranged from 83% in the group who lost >5 kg, to 88% in the weight neutral group (log-rank test P value = .0005). These events are summarised in Table 2 .
| Risk of composite cardiovascular outcomes
The hazard of the 3-point composite outcome of nonfatal AMI, nonfatal stroke, and all-cause mortality was compared with the no weight change group ( The proportional hazard assumptions of the Cox-regression analysis were tested by adding by comparing the cumulative hazard plot groups on the exposure group, including an interaction term of the predictor and log time and also by using Schoenfeld residuals test. We observed no violations as both were found to be nonsignificant and satisfied the proportional hazard assumption. Table 2 . Compared with the weight-neutral group, the adjusted risk of composite CV risk and all-cause mortality event was 50% (aHR:
1.50, 95% CI: 1.08-2.08) more in the obese population group who lost greater than 5 kg at 1 year postinsulin initiation compared with the weight-neutral group. Similarly, a nonsignificant increase of 27%, 14%, and 29% in this risk was, however, reported in the 1 to 5 kg weight loss, 1 to 5 kg weight gain, and >5 kg weight gain groups as shown in Table 2 .
3.5.2 | Risk of mortality, nonfatal myocardial infarction, and nonfatal stroke
The events and hazards of the components of the 3-point composite event are shown in Table 3 .
Sensitivity analyses comparing the hazards of the composite events between the weight-change categories ranked in quintiles showed similar pattern in the risk of the 3-point composite event.
Similarly, we obtained similar results and trend in risk of the composite outcome and individual components of the 3-point composite outcome when we compared the incomplete and imputed datasets. This affirmed that the imputation robustly addressed the missing data. (17) 177 (18) 686 (18) 790 (17) 3,280 (17) Heart failure 568 (14) 712 (13) 138 (14) 518 (13) 663 (15) 2,599 (13.9) PAD 522 (13) 688 (13) 130 (13) 511 (13) 660 (14) 2,511 (13. weight change across different baseline weight categories, a previous study using a US-based electronic medical record reported that a reduction in HbA 1c was associated with progressively less weight gain as baseline BMI rose. 18 The inference from that study that the lesser weight gain seen in obese patients was due to the use of less intensive insulin therapy may also apply to this cohort.
Although it seems logical that weight gained in people with diabetes, a disease with a high incidence of CV risk, would increase CV 20 Thus, patient factors associated with persistently high HbA 1c , despite intensive treatment, appear to be the most important determinant of increased mortality risks. To this end, insulininduced weight gain in our study was seen to be associated with a reduction in HbA 1c , while those who lost weight were associated with a deterioration or unchanged HbA 1c levels (Figure 3 ).
Three possible explanations could be inferred from this observation. First, a rise in HbA 1c levels may dilute any favourable impact of weight reduction and lead to an increase in CV events. In support of this, there is evidence that intensive control of blood glucose levels in patients with T2D reduces the long-term risk of adverse CV events. 21, 22 These benefits may take many years to become apparent Nevertheless, we contend that there is indirect evidence that failure to achieve HbA 1c reduction, irrespective of the evidence for this, should be used as a trigger to intensify CV risk reduction strategies. Composite outcome includes all-cause mortality, nonfatal acute myocardial infarction (AMI), and nonfatal stroke.
b Adjusted for age, diabetes duration diastolic and systolic blood pressure, height, weight, albumin, glomerular filtration rate, gender, smoking status, alcohol status, lipid profile, Townsend deprivation score, number of glucose-lowering therapies, lipid-lowering therapies, antihypertensives, heart failure, and peripheral artery disease.
FIGURE 2
Kaplan-Meier curve showing the probability of survival between the weight-change categories within the follow-up period. Log-rank test P value = .0005
Our study findings are in keeping with the outcome of another real world study in Australia, which showed that insulin-induced weight gain was not associated with adverse changes in CV risk factors after 1 year of insulin initiation. 27 Our data, however, are in con- These studies, however, did not focus on patients with T2D receiving insulin therapy. Two previous studies in patients with T2D have not observed adverse CV risk factors following insulin-induced weight gain. 30, 31 In this context, while weight gain has to be viewed as an undesirable side effect of insulin therapy, it appears to be associated with adverse CV outcome in patients with type 1 diabetes but possibly not in patients with T2D.
Our analyses were subject to a number of limitations that are inherent to observational studies. First, we cannot be certain that the patients in this cohort were fully compliant with their medication. Also, some factors like lifestyle and dietary intervention and records of comorbidities as cancers and metabolic disorders (which were not so robustly included in our data) may influence our findings. We were also not able to obtain longitudinal insulin doses, an important predictor of insulin-induced weight gain. 32 Because our aim was to look at status of weight change due to insulin initiation per se on CV outcomes, we would argue that this should not influence the robustness of our FIGURE 3 Relationship between change in weight and glycaemic control. This figure illustrates the association between glycaemic control (measured by the difference between baseline HbA 1c and level after 1 year of insulin initiation) and change in weight after 1 year of initiation of insulin in naïve insulin users. For a unit increase in weight at 1 year postinsulin initiation, there was a marginal but significant reduction in HbA 1c (r: −0.005%, 95% CI: −0.007 to −0.002%; P value: .001) findings. Although we could not account for potential residual confounders such as compliance, indications for intensification treatments, markers of β-cell deterioration, and frequency of hypoglycaemia, we were able to account for differences in the observed covariates and used robust analytical techniques to control confounding that may bias the results of the estimated treatment effects.
In conclusion, we observed that in the group that experienced weight gain following insulin treatment, insulin-induced weight gain was not associated with adverse CV outcomes as indirectly suggested in previous clinical trials. These findings should provide important reassurance among patients with T2D who gained weight following insulin treatment in routine clinical practice.
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NOVELTY STATEMENT
• What is already known: Despite the well-recognised correlation between weight gain and cardiovascular (CV) disease, as well as insulin-induced weight gain, there is little direct evidence relating to the impact of insulin-induced weight gain on CV outcomes.
• What this study adds: This study robustly investigates the impact of insulin-induced weight gain on the 5 year risk of CV outcome and mortality.
• Weight loss >5 kg in insulin users was associated with up to 31%
higher risk of a 3-point composite of mortality, nonfatal acute myocardial infarction (MI), and nonfatal stroke.
• We observed that although insulin treatment was indeed associated with weight gain, this did not translate to adverse CV outcomes and mortality in patients with T2D and so provides reassurance on the cardiovascular safety of insulin-induced weight gain in these patients.
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